Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in RXRX held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 43.2M | $132.6M | +11.1% | 9.659% | 0.00% |
| 2 | ARK Investment Management LLC | 40.2M | $123.5M | +7.8% | 8.992% | 0.96% |
| 3 | STATE STREET CORP | 28.5M | $87.5M | +12.5% | 6.371% | 0.00% |
| 4 | BAILLIE GIFFORD & CO | 23.7M | $72.7M | -0.4% | 5.294% | 0.07% |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 22.8M | $69.9M | β | 5.089% | 0.00% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 22.2M | $68.3M | β | 4.974% | 0.00% |
| 7 | SOFTBANK GROUP CORP | 13.6M | $41.9M | 0.0% | 3.049% | 0.37% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 12.3M | $37.7M | +12.3% | 2.745% | 0.00% |
| 9 | MIC Capital Management UK LLP | 9.6M | $29.6M | 0.0% | 2.157% | 8.40% |
| 10 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 8.4M | $25.7M | -7.5% | 1.875% | 0.00% |
| 11 | GOLDMAN SACHS GROUP INC | 6.1M | $18.6M | +175.5% | 1.356% | 0.00% |
| 12 | Data Collective IV GP, LLC | 5.9M | $18.2M | 0.0% | 1.329% | 32.60% |
| 13 | Exor Capital LLP | 5.9M | $18.1M | +19.3% | 1.315% | 0.36% |
| 14 | Sumitomo Mitsui Trust Holdings, Inc. | 5.4M | $16.6M | -12.9% | 1.212% | 0.01% |
| 15 | Nikko Asset Management Americas, Inc. | 5.4M | $16.6M | -12.9% | 1.212% | 0.23% |
| 16 | UBS Group AG | 5.1M | $15.8M | +37.7% | 1.150% | 0.00% |
| 17 | TWO SIGMA INVESTMENTS, LP | 4.1M | $12.5M | +32.2% | 0.909% | 0.01% |
| 18 | UBS ASSET MANAGEMENT AMERICAS INC | 4.0M | $12.4M | -1.3% | 0.900% | 0.00% |
| 19 | NORTHERN TRUST CORP | 4.0M | $12.2M | +15.4% | 0.887% | 0.00% |
| 20 | DCVC Opportunity Fund II GP, LLC | 4.0M | $12.1M | 0.0% | 0.884% | 87.48% |
| 21 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 3.8M | $11.7M | -4.7% | 0.852% | 0.00% |
| 22 | VANGUARD FIDUCIARY TRUST CO | 3.5M | $10.8M | β | 0.786% | 0.00% |
| 23 | MARSHALL WACE, LLP | 2.9M | $8.8M | +1169.6% | 0.643% | 0.01% |
| 24 | MILLENNIUM MANAGEMENT LLC | 2.6M | $8.0M | +74.6% | 0.584% | 0.01% |
| 25 | FIRST TRUST ADVISORS LP | 2.6M | $8.0M | +15.2% | 0.584% | 0.01% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in RXRX β a direct measure of their conviction.
Filings activity in RXRX during Q1 2026, grouped by how each filer changed its position.
Institutions that opened a new RXRX position in Q1 2026
Institutions that fully closed their RXRX position in Q1 2026
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 331 | +1.5% | 73.30% | 22.45 pp | $1.03B | 23% |
| Q4 2025 | 326 | +4.8% | 95.75% | 19.93 pp | $1.35B | 17% |
| Q3 2025 | 311 | 4.0% | 115.68% | +3.79 pp | $1.63B | +3.4% |
| Q2 2025 | 324 | 1.8% | 111.89% | 1.41 pp | $1.58B | 1.2% |
| Q1 2025 | 330 | +6.8% | 113.30% | 32.15 pp | $1.60B | 22% |
| Q4 2024 | 309 | +19% | 145.45% | +25.52 pp | $2.05B | +21% |
| Q3 2024 | 260 | 1.9% | 119.93% | 13.57 pp | $1.69B | 10% |
| Q2 2024 | 265 | β | 133.50% | β | $1.88B | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying RXRX stock.
Based on Q1 2026 13F filings, institutional ownership of Recursion Pharmaceuticals, Inc. stands at 73.3%, held across 331 reporting institutions.
BlackRock, Inc. is the largest reported institutional holder of RXRX, with approximately 43,192,306 shares worth $0.13B as of Q1 2026.
Yes β 4 widely-followed marquee investors appear among the top 25 institutional holders of RXRX, including ARK Investment Management LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, TWO SIGMA INVESTMENTS, LP, MILLENNIUM MANAGEMENT LLC.
Our composite Smart Money Score for RXRX is 52 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
63 institutions opened new positions in RXRX during Q1 2026, while 58 fully exited. 58 added to existing positions and 209 trimmed.
RXRX institutional ownership fell by 22.45 percentage points quarter-over-quarter, with a net change of +5 holders.
The top 10 institutions account for 66.8% of all reported 13F value in RXRX, and the top 25 account for 86.2%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Recursion Pharmaceuticals, Inc. (RXRX) Institutional Ownership